Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | PLG | P00747 | 4/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460224 | 0.95 | IGF1R (0.37) | IGF1RBCHETNK2 | |
| SCHEMBL2461856 | 0.93 | IGF1R (0.39) | IGF1RBCHEPLGPRSS1PRSS2 | |
| SCHEMBL2459434 | 0.93 | HTR6 (0.40) | IGF1RBCHETNK2HTR6 | |
| SCHEMBL4145255 | 0.92 | TNK2 (0.38) | IGF1RBCHETNK2HTR6MEN1 | |
| SCHEMBL2457346 | 0.92 | IGF1R (0.38) | IGF1RBCHETNK2HTR6 | |
| SCHEMBL2464604 | 0.91 | IGF1R (0.40) | IGF1RBCHETNK2KDM4ESMN1; SMN2 | |
| SCHEMBL2467426 | 0.90 | TNK2 (0.40) | IGF1RBCHETNK2 | |
| SCHEMBL2462722 | 0.90 | BCHE (0.39) | IGF1RBCHETNK2MEN1KMT2A | |
| SCHEMBL2459972 | 0.89 | IGF1R (0.40) | IGF1R | |
| SCHEMBL2463565 | 0.89 | IGF1R (0.38) | IGF1RBCHETNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | claimed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | claimed |
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885BCHE 4603/4885PLG 4414/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885BCHE 4603/4885PLG 4414/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | IGF1R 1/4885BCHE 4603/4885PLG 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.